New CMO in Pharma Equity Groups subsidiary Reponex Pharmaceuticals A/S
14 Junio 2023 - 1:30AM
New CMO in Pharma Equity Groups subsidiary Reponex Pharmaceuticals
A/S
14 June 2023
Press Release
New CMO in Pharma Equity Groups subsidiary
Reponex Pharmaceuticals A/S
We are delighted to present Dr Christopher M
Burton MD, PhD, (born 1973) an accomplished and results-driven
industry physician with extensive experience in clinical research
and development, as our new Chief Medical Officer, CMO, and an
important addition to Reponex senior management team.
Dr Burton brings a wealth of expertise in
developing strategies for pharmaceutical products, encompassing all
phases of development from discovery to market. His professional
medical career spans 25 years, having qualified as a medical doctor
from Imperial College, London in 1998. Dr Burton worked for several
years in clinical medicine to the level of registrar, is a Member
of the Royal College of Physicians, and has international clinical
experience from working in hospitals in England, Australia, and
Denmark. He subsequently completed a PhD in transplant immunology
at University of Copenhagen, before transitioning to the
pharmaceutical industry in 2007.
During his industry career, Dr Burton has
experience from both large and mid-sized pharmaceutical companies
(Novo Nordisk and ALK), as well as small MedTech and biotech
companies. Dr Burton has also provided clinical development and
medical affairs consultancy services to a wide range of
pharmaceutical clients supporting global, regional, or national
initiatives across a range of therapeutic indications linked to
inflammation, immunology, metabolic disease, and haematological and
solid organ malignant disease. He has previously been involved in
the development and commercialization of global brands and has a
global network and contacts with key opinion leaders and
pharmaceutical industry professionals.
With a solid foundation in line management and
project leadership from diverse medical roles within the
pharmaceutical industry, in addition to his earlier professional
experience in clinical medicine and academic research, Dr Burton
brings valuable expertise to Reponex's drug development
endeavours.
Dr Burton has a track record of achieving
ambitious research and commercial goals. He has specific clinical
development experience of working with one of Reponex’s pipeline
candidate pharmaceuticals.
Reponex is an organization focused on achieving
clinical development goals through an efficient and agile approach.
Our new Chief Medical Officer embodies these attributes with a
versatile analytical and clinical skill set, and an extensive
network of pharmaceutical professionals and opinion leaders. Dr
Burton’s integrated competencies and solid work history promises to
drive long-standing value contributions to Reponex.
Please see https://youtu.be/jqAi_0Mi1jQ for a
digital presentation of Dr Christopher M Burton
"We are very pleased that it has been possible
to bring Dr Christopher M. Burton into Reponex. Christopher
Burton’s extensive clinical and industry experience and research
expertise will strengthen the company as we progress the
development of our clinical stage therapeutics,” says Thomas Kaas
Selsø, CEO.
Changes in the executive management in
Reponex Pharmaceuticals A/S
Professor Søren Nielsen has been the interim CEO
in Reponex since 11 October 2022 and has formerly been in the board
of directors for Reponex. Professor Nielsen has chosen to
focus his future efforts to support AKI Therapeutics A/S and in
RepoCeuticals A/S. Therefore, it has been decided that Thomas Kaas
Selsø, who is already CEO of Pharma Equity Group, will take over as
CEO of Reponex.
We would like to take this opportunity to thank
Professor Søren Nielsen for his great contributions to the company
over the years, and we wish him all the best for the future.
About Pharma Equity Group A/S
Pharma Equity Group A/S is a listed company on
the Nasdaq Copenhagen Stock Exchange, with a focus on early
investment in innovative life science companies (in or before phase
2) that develop technologies and therapies that have the potential
to improve human health and quality of life.
Pharma Equity Group A/S portfolio currently
includes Reponex Pharmaceuticals A/S. Reponex Pharmaceuticals A/S
is a clinical-stage biopharmaceutical company dedicated to the
development of novel, effective treatments for diseases that have
significant patient and social impact.
Pharma Equity Group A/s (LSE:0REU)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Pharma Equity Group A/s (LSE:0REU)
Gráfica de Acción Histórica
De May 2023 a May 2024
